Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint how Genpact recognizes contract revenue or which segment drives its digital transformation growth? With subsidiaries across 25+ countries, Genpact鈥檚 disclosures can stretch beyond 250 pages, and the footnotes on long-term service contracts, Data-Tech-AI investments, and client concentration often hide deep inside. If you鈥檙e searching for 鈥淕enpact SEC filings explained simply,鈥� this page delivers. Stock Titan surfaces the answers in seconds.
Our AI-powered summaries translate every Genpact SEC document鈥攆rom an 8-K on a new outsourcing deal to the annual report 10-K鈥攊nto plain language. Whether you search 鈥淕enpact insider trading Form 4 transactions鈥� or 鈥渦nderstanding Genpact SEC documents with AI,鈥� you鈥檒l find real-time insights, keyword tagging, and cross-linking that make navigation effortless.
Need the latest numbers? The 鈥淕enpact quarterly earnings report 10-Q filing鈥� section highlights revenue by vertical, margin movement, and cash-flow trends, while our dashboards compare quarter-over-quarter performance. For governance questions, the proxy statement area breaks down Genpact executive compensation, option awards, and CEO pay ratio. Monitoring management moves? Get instant alerts on 鈥淕enpact Form 4 insider transactions real-time鈥� so you never miss a buyback or stock grant.
Every filing type is covered and explained:
- 10-K annual report鈥攕trategy shifts, customer concentration, risk factors simplified (鈥淕enpact annual report 10-K simplified鈥�).
- 10-Q quarterly update鈥攄ata tables annotated, segment commentary summarized (鈥淕enpact earnings report filing analysis鈥�).
- 8-K material events鈥攃ontract wins or leadership changes distilled (鈥淕enpact 8-K material events explained鈥�).
- Form 4鈥攅xecutive stock moves tracked live (鈥淕enpact executive stock transactions Form 4鈥�).
- DEF 14A proxy鈥攂oard structure and incentive plans clarified (鈥淕enpact proxy statement executive compensation鈥�).
Stop scrolling through PDFs. Stock Titan delivers real-time filing updates, context-rich charts, and expert analysis tailored to Genpact鈥檚 business-process management model鈥攕o you can focus on decisions, not document hunting.
Donald J. Klunk, identified as Chief Accounting Officer, reported two non-derivative transactions in Genpact Limited (G). On 09/02/2025 1,468 shares were withheld for taxes upon vesting of restricted share units at a price of $45.34, leaving 10,135 shares beneficially owned after that transaction. On 09/03/2025 he sold 2,695 shares at $44.77, leaving 7,440 shares beneficially owned following the sale. The filing notes 252 shares were acquired under the Genpact Employee Stock Purchase Plan since his prior Form 4 on March 13, 2025, and he currently holds 673 ESPP shares. The form is signed by an attorney-in-fact on 09/04/2025.
Genpact Limited (G) notice: an individual who received 2,695 restricted common shares from the issuer on 08/31/2025 intends to sell those shares on or about 09/03/2025. The filer lists Morgan Stanley Smith Barney LLC as the broker and values the shares' aggregate market value at $120,641.68 based on outstanding common shares of 174,270,076. The filing reports no other sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Genpact Limited (G) insider transaction: Sameer Dewan, Senior Vice President, reported selling 20,078 common shares on 08/28/2025 at $45 per share, leaving him with 89,148 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The filing shows a direct disposition of shares and does not disclose any derivative transactions or a 10b5-1 plan.
Genpact Limited (G) submitted a Form 144 notifying a proposed sale of 20,078 common shares via Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $903,510 and an approximate sale date of 08/28/2025. The filing shows the shares were acquired on 01/10/2025 from the issuer as 12,236 restricted stock and 7,842 performance shares, with payment dates listed as 01/10/2025 and no cash financing arrangements disclosed. The total outstanding common shares noted are 174,270,076, so the proposed sale represents a de minimis portion of the outstanding float. The filer certifies no undisclosed material adverse information and no sales in the past three months are reported.
Anil Nanduru, Senior Vice President at Genpact Limited (G), reported two open-market sales of company common shares on Aug 21鈥�22, 2025. He sold 18,218 shares on 08/21/2025 at $44.50 per share and 9,744 shares on 08/22/2025 at $45.50 per share, reducing his beneficial ownership to 89,846 common shares after the transactions. The filing notes that his total holdings include 237 shares received via dividend reinvestment since his prior Form 4. The Form 4 is signed by an attorney-in-fact for the reporting person.
Genpact Limited insider Form 4: Senior Vice President Riju Vashisht reported two open-market sales of Genpact (G) common shares on 08/22/2025. The first sale disposed of 17,608 shares at a weighted average price of $45.61, leaving 130,201 shares beneficially owned. The second sale disposed of 7,931 shares at a weighted average price of $45.57, leaving 122,270 shares beneficially owned. The combined number of shares sold was 25,539. The form notes the price ranges for the sales and discloses the reporting person holds 4,154 shares via the Employee Stock Purchase Plan, including 160 shares acquired since the prior Form 4. The filing was signed by an attorney-in-fact on 08/25/2025.
Form 144 notice indicates a proposed sale of 9,744 common shares through Morgan Stanley Smith Barney on 08/22/2025 with an aggregate market value of $443,352.00. The shares were acquired as restricted stock from the issuer on 01/10/2025 and paid for on that date. The filer disclosed two prior sales on 08/21/2025 totaling 18,218 shares for gross proceeds of $810,701.00 (listed as $505,119.50 and $305,581.50). The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Form 144 notice for Genpact Limited (symbol: G) discloses a proposed sale of 25,539 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $1,164,468.47 and approximately 174,270,076 shares outstanding. The shares were acquired as performance shares: 17,608 on 01/10/2022 and 7,931 on 01/10/2023. No securities were reported sold by the selling person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information and follows the Rule 144 disclosure process.
Genpact Limited (G) filing a Form 144 notifies the proposed sale of 18,218 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $810,701.00. The shares were granted as performance shares and were acquired in two tranches: 11,351 on 01/10/2022 and 6,867 on 01/10/2023. The filing lists 174,270,076 shares outstanding for the class and indicates no reported sales by the seller in the past three months. The notice includes the seller鈥檚 representation that they are not aware of undisclosed material adverse information.
Carol Lindstrom, a director of Genpact Limited (ticker G), reported a sale of 2,326 common shares on 08/12/2025 at $43.17 per share. After the disposition she beneficially owned 21,185 shares directly. The filing is limited to a single non-derivative sale and shows no option or derivative activity.
FAQ
What is the current stock price of Genpact (G)?
What is the market cap of Genpact (G)?
